Twist Bioscience Corporation (TWST)
Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation multiples now appear more reasonable, making it a compelling buy for new investors, with a long cash runway and potential self-sustainability by 2025-2026. The company has improved its gross margins and reduced EBIT margins, signaling rapid margin improvement and benefiting from economies of scale.
Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. The company's future relies on its synthetic biology segment, facing competition and uncertain prospects in a rapidly evolving market.
Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Patrick Finn - President and COO Conference Call Participants Steven Mah - Cowen Matt Larew - William Blair Luke Sergott - Barclays Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Puneet Souda - Leerink Partners Tom Peterson - Baird Thomas DeBourcy - Nephron Research Operator Good day, and thank you for standing by. Welcome to Twist Bioscience Fiscal 2024 Third Quarter Financial Results Conference Call.
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $1.01 per share a year ago.
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.
